CD8A and melanoma: In melanoma samples before treatment with the PD1 specific antibody pembrolizumab, several immune features were associated with subsequent clinical responses, i.e. enrichments of CD8-, PD1-, and PD-L1-expressing cells inside tumors and at invasive margins, with close proximity of PD1/PD-L1, and increased TCR diversity (141).